You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Iodophenpropit dihydrobromide
Iodophenpropit dihydrobromide is a selective H3 antagonist with high affinity (KD = 0.3 nM).
Sold with the permission of SCI, Amsterdam
Technical Data for Iodophenpropit dihydrobromide
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Iodophenpropit dihydrobromide
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Iodophenpropit dihydrobromide
The following data is based on the product molecular weight 576.13. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.25 mM||6.94 mL||34.71 mL||69.43 mL|
|1.25 mM||1.39 mL||6.94 mL||13.89 mL|
|2.5 mM||0.69 mL||3.47 mL||6.94 mL|
|12.5 mM||0.14 mL||0.69 mL||1.39 mL|
Product Datasheets for Iodophenpropit dihydrobromide
References for Iodophenpropit dihydrobromide
References are publications that support the biological activity of the product.
Jansen et al (1992) The first radiolabelled histamine H3 receptor antagonist, [125I]iodophenpropit: saturable and reversible binding to rat cortex membranes. Eur.J.Pharmacol. 217 203 PMID: 1330590
Jansen et al (1994) Characterisation of the binding of the first selective radiolabelled histamine H3 receptor antagonist, [125I]-iodophenpropit, to rat brain. Br.J.Pharmacol. 113 355 PMID: 7834183
Menge et al (1992) Synthesis of S-[3-(4(5)-imidazolyl)propyl]-N-[2-(4-[125I]-iodophenylethyl]isothiourea sulfate [125I]-iodophenpropit), a new probe for histamine H3 receptor binding sites. J.Labelled Comp.Radiopharm. XXXI 10 781
Shahid et al (2009) Histamine, histamine receptors, and their role in immunomodulation: An updated systematic review. Open Immunol.J. 2 9
If you know of a relevant reference for Iodophenpropit dihydrobromide, please let us know.
View Related Products by Product Action
Keywords: Iodophenpropit dihydrobromide, Iodophenpropit dihydrobromide supplier, Potent, selective, H3, antagonists, Receptors, Histamine, histaminergic, 0779, Tocris Bioscience
2 Citations for Iodophenpropit dihydrobromide
Citations are publications that use Tocris products. Selected citations for Iodophenpropit dihydrobromide include:
Otvos et al (2015) Development of Plate Reader and On-Line Microfluidic Screening to Identify Ligands of the 5-Hydroxytryptamine Binding Protein in Venoms. BMC Neurosci 7 2336 PMID: 26114334
Spaethling et al (2014) Serotonergic neuron regulation informed by in vivo single-cell transcriptomics. Toxins (Basel) 28 771 PMID: 24192459
Do you know of a great paper that uses Iodophenpropit dihydrobromide from Tocris? Please let us know.
Reviews for Iodophenpropit dihydrobromide
There are currently no reviews for this product. Be the first to review Iodophenpropit dihydrobromide and earn rewards!
Have you used Iodophenpropit dihydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.